Ciclesonide (Alvesco®) - a new glucocorticosteroid for inhalative treatment

Andrea Gotzmann, Mario Thevis, Michael Bredehöft, Wilhelm Schänzer

Publication: Chapter in Book/Report/Conference proceedingConference contribution - Article for conferenceResearch


Since January 2005 Ciclesonide [CIC], a new, nonhalogenated inhalative glucocorticoid to treat the inflammation associated with persistent asthma is marketed. The respective formulation Alvesco® is available for adults and should be applied once a day via inhaler. Ciclesonide is administered as inactive parent compound to the lung and is there converted to its active metabolite desisobutyryl-ciclesonide [des-CIC]. Des-CIC has a high affinity for the glucocorticoid receptor, comparable to budesonide and fluticasone propionate. It is rapidly converted by CYP3A4 into a series of polar metabolites in the liver. The pro-drug CIC as well as its active metabolite des-CIC have been implemented into the existing screening procedure for glucocorticosteroids in human doping analysis. Studies regarding specificity, limit of detection, recovery, and robustness have been performed for the detection of CIC and des-CIC in human urine and satisfactory results were obtained. Verf.-Referat
Original languageEnglish
Title of host publicationRecent advances in doping analysis (14) : Proceedings of the Manfred Donike Workshop ; 24th Cologne Workshop on Dope Analysis 4th to 9th June 2006
EditorsWilhelm Schänzer, Hans Geyer, A. Gotzmann, Ute Mareck
Number of pages7
PublisherSport & Buch Strauß
Publication date2006
Publication statusPublished - 2006
EventCologne Workshop on Dope Analysis - Köln, Germany
Duration: 04.06.200609.06.2006
Conference number: 24


Dive into the research topics of 'Ciclesonide (Alvesco®) - a new glucocorticosteroid for inhalative treatment'. Together they form a unique fingerprint.